Followers | 827 |
Posts | 119499 |
Boards Moderated | 15 |
Alias Born | 09/05/2002 |
Friday, September 02, 2016 2:38:29 PM
[Updates:
2016-2017 news flow;
USPTO invalidates three of Teva’s 40mg Copaxone patents;
launch of 40mg Glatopa likely in early 2017;
handicapping the 40mg-Copaxone market;
five 40mg-Copaxone patents to be litigated in District Court.]
CORPORATE AND FINANCIAL
What is MNTA’s business all about?
#msg-119915120 MNTA’s drug portfolio and pipeline
#msg-124941909 2016-2018 possible/probable events
#msg-124323319 Transcript of 2Q16 CC (8/4/16)
#msg-119915029 Webcast on MNTA-MYL partnership for FoBs (1/8/16)
#msg-49883723 MNTA is a beneficiary of US FoB legislation
#msg-26837144 Momenta’s mantra on interchangeable FoBs
#msg-122395849 FDA PoV on interchangeable FoBs may have moved in MNTA’s favor
#msg-124305076 MNTA discontinues Necuparanib program in pancreatic cancer
#msg-25803923 The Pink Sheet interviews Craig Wheeler (dated, but still a good read)
Valuation and finances
#msg-124348392 MNTA has strong liquidity
#msg-124305312 2Q16 press release
#msg-114728853 Glatopa milestone payments from NVS
#msg-124349021 Diluted share count for valuation purposes
#msg-124870976 NVS’ equity stake
Officers and directors
#msg-123485297 Composition of Board of Directors
#msg-118984568 Former Biogen executive, Matt Ottmer, named COO (12/15)
#msg-94898356 Michael Franken named head of FoB program (12/13)
#msg-58383722 Young Kwon named VP, Business Development (1/11)
#msg-33979910 James Sulat named Chairman of BoD (12/08)
#msg-27338039 James Roach, CMO, joins MNTA (2/08)
#msg-12824293 Craig Wheeler, CEO, joins MNTA from Chiron (8/06)
FOLLOW-ON BIOLOGICS (FoB) PROGRAM
#msg-104534644 FoBs will be $35B market by 2020
#msg-119689602 MNTA inks 50/50 partnership with Mylan for 6 FoBs
#msg-119691929 Terms of partnership meet two of MNTA’s stated goals
#msg-119697433 Commentary on MNTA-MYL partnership by FierceBiotech
#msg-122395849 FDA PoV on interchangeable FoBs may have moved in MNTA’s favor
#msg-110925786 MNTA’s partner is SHPG (formerly Baxter) for Humira FoB
#msg-122391552 Effect of SHPG-BXLT merger on Humira FoB program
#msg-70237561 An interchangeable Humira FoB has colossal upside
#msg-117482545 MNTA/SHPG start phase-3 trial of Humira FoB
#msg-123165310 Final phase-1 bioequivalence data for Humira FoB
#msg-118781959 Can Abbvie block US Humira FoBs until 2022?
#msg-119852113 Abbvie wins USPTO ruling vs Amgen on Humira…
#msg-122698047 …but loses (preliminary) USPTO action vs Coherus
#msg-48581353 Affordable Care Act (ObamaCare) enables US FoBs
#msg-26837144 Momenta’s mantra on interchangeable FoBs
#msg-122623720 FDA proposes dedicated unit to evaluate FoBs
#msg-123094763 FDA guidance documents wrt FoBs
#msg-70191760 US patent-expiration dates of big-selling biologics
GLATOPA (COPAXONE) PROGRAM
Economic rationale and profit split
#msg-12222305 NVS/MNTA split Glatopa profits 50/50
#msg-113300123 MNTA guides to $35K revenue per Glatopa patient-year
#msg-114728853 Glatopa milestone payments from NVS
20mg Glatopa
#msg-112799454 FDA approves 20mg Glatopa
#msg-112799896 FDA’s rationale for approval of 20mg Glatopa
40mg Glatopa
#msg-120661209 NVS/MNTA’s 40mg ANDA has 2016 GDUFA date
#msg-124820193 “At risk” launch likely in early 2017 (if ANDA approved)
#msg-124918501 USPTO invalidates three of Teva’s 40mg Copaxone patents
#msg-124628031 Five 40mg-Copaxone patents will be litigated in US District Court
#msg-124749893 Handicapping the 40mg-Copaxone market
Potential competition from other generic Copaxone products
#msg-112812696 No FDA roadmap for competing generics
#msg-112887376 MNTA’s Copaxone IP may thwart other generics
#msg-112817624 Musings on likelihood of competition from other generics (MTB)
#msg-112848073 Musings on likelihood of competition from other generics (indigokid)
#msg-115996641 Mylan admits it has work to do on Copaxone ANDA
#msg-90636221 Mylan and MNTA products are not identical
#msg-119705776 New inference that Mylan not close to FDA approval
#msg-29902618 Mylan inks Copaxone deal with India’s Natco (Jun 2008)
#msg-41441618 FDA accepts Mylan’s Copaxone ANDA for review (Sep 2009)
#msg-115896634 PFE licenses Synthon’s Copaxone ANDA
#msg-70039774 Synthon submits Copaxone ANDA…
#msg-99675480 …but acknowledges receiving an unresolved CRL
LOVENOX PROGRAM
#msg-118404904 CAFC remands Lovenox patent case to District Court for trial (1)
#msg-118397347 CAFC remands Lovenox patent case to District Court for trial (2)
#msg-123721732 New patent trial to begin in late 2017 or 2018
#msg-118462482 Amphastar changes its tune on Court bond
#msg-114749299 NVS/MNTA split Lovenox profits/damage awards 50/50
ENHANCED-IVIG PROGRAM
#msg-111515491 What is IVIG? (short videos)
#msg-107107809 Structure & rationale for MNTA’s compounds (slides 118-131)
#msg-123192434 MNTA starts phase-1 trial of M281 (FcRn antagonist)
#msg-101443478 Preclinical data on IVIG program
#msg-69595597 MNTA acquires sialic switch IP from Virdante Pharmaceuticals
#msg-69681347 Musings on the Virdante deal
#msg-106041077 MNTA exercises Anaptys option
INTELLECTUAL PROPERTY
#msg-84501925 Musings on trade secrets and FDA disclosure policy
#msg-111389703 Recent patent applications and overview of IP estate
#msg-59682546 USPTO issues ‘187 patent re Copaxone manufacturing
#msg-112887376 MNTA’s Copaxone IP may thwart other generics
#msg-89344512 USPTO issues sialylation patent licensed to MNTA
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM